bronchiol
obliteran
syndrom
constrict
bronchiol
obliteran
lymphocyt
bronchiol
lung
histolog
chronic
gvhd
lung
b
r
c
bronchiol
obliteran
bo
sever
complic
allogen
hematopoiet
stem
cell
transplant
unfavor
prognosi
lung
biopsi
remain
gold
standard
diagnosi
retrospect
singlecent
studi
describ
patient
underw
biopsi
suspect
bo
ten
patient
constrict
bo
cbo
lymphocyt
bronchiol
lb
character
lymphocyt
infiltr
bronchiol
six
addit
patient
cbo
lb
concomit
infect
patholog
diagnos
seven
patient
cbo
lb
met
nation
institut
health
consensu
bo
syndrom
definit
criteria
addit
patient
histolog
confirm
cbo
meet
consensu
definit
concomit
airway
infect
diagnosi
signific
differ
cbo
lb
group
clinic
present
pulmonari
function
test
median
forc
expiratori
volum
one
second
baselin
predict
time
videoassist
thoracoscop
surgeri
cbo
lb
group
respect
chest
scan
treatment
similar
group
outcom
differ
depend
histolog
find
significantli
improv
lb
patient
compar
cbo
patient
surviv
year
ae
ae
patient
cbo
ae
patient
lb
p
lung
biopsi
patient
suspect
bo
enabl
better
character
pattern
bo
syndrom
contrast
cbo
lb
associ
good
longterm
prognosi
despit
care
patient
select
hematopoiet
stem
cell
transplant
hsct
improv
support
care
transplantationrel
mortal
mainli
due
infect
graftversushost
diseas
gvhd
remain
major
issu
pulmonari
complic
common
associ
signific
morbid
mortal
acut
posttransplant
complic
relat
infect
although
noninfecti
pulmonari
toxic
contribut
late
complic
becom
increasingli
recogn
lung
injuri
infecti
noninfecti
acut
chronic
manifest
either
restrict
obstruct
lung
function
pattern
late
pulmonari
complic
often
associ
chronic
gvhd
bronchiol
obliteran
syndrom
bo
complic
increas
incid
recent
year
reason
increas
complet
understood
might
partial
explain
success
treatment
posttransplant
complic
therebi
expos
patient
risk
bronchiol
obliteran
bo
increas
use
unrel
donor
addit
differ
incid
bo
part
due
diagnost
method
risk
factor
develop
bo
includ
pretransplant
lung
function
type
intens
condit
regimen
use
peripher
blood
stem
cell
immunoglobulin
level
respiratori
infect
moreov
occurr
gvhd
site
associ
bo
pathogenesi
bo
complet
understood
specif
immun
reaction
donor
cell
addit
recipi
innat
immun
system
thought
play
role
develop
bo
accord
nation
institut
health
nih
consensu
statement
criteria
bo
consid
diagnost
pulmonari
gvhd
bo
clinic
diagnos
follow
criteria
met
forc
expiratori
volum
second
forc
vital
capac
fvc
ratio
predict
valu
evid
air
trap
small
airway
thicken
bronchiectasi
highresolut
chest
comput
tomographi
hrct
residu
volum
patholog
confirm
constrict
bronchiol
absenc
respiratori
tract
infect
boorgan
pneumonia
due
infect
may
repres
manifest
either
acut
chronic
gvhd
consid
common
featur
nevertheless
diagnosi
pulmonari
chronic
gvhd
remain
challeng
gold
standard
remain
biopsyproven
bo
howev
known
histolog
result
patient
bo
associ
sever
diseas
outcom
diagnos
intens
longterm
immunosuppress
gener
recommend
proven
bo
howev
prognosi
unfavor
mainli
late
definit
diagnosi
resist
therapi
progress
deterior
lung
function
death
common
either
due
infect
andor
respiratori
failur
earli
test
prognost
impact
therefor
urgent
need
hypothesi
histolog
may
defin
diseas
sever
predict
outcom
patient
bo
therefor
review
lung
biopsi
routin
perform
patient
clinic
suspicion
bo
analyz
histolog
pattern
correl
clinic
characterist
potenti
impact
biopsi
result
predict
patient
outcom
guid
patient
manag
singlecent
cohort
studi
includ
consecut
patient
underw
lung
biopsi
suspect
bo
allogen
hsct
januari
decemb
period
patient
underw
allogen
hsct
center
lung
biopsi
diagnos
exclud
bo
consid
treat
physician
patient
respiratori
symptom
declin
lung
function
test
result
exclus
infect
differenti
diagnos
hrct
scan
bronchoalveolar
lavag
bal
pulmonari
function
test
pft
usual
perform
patient
use
bodi
plethysmographi
jaeger
hoechberg
germani
transplant
baselin
month
month
year
transplant
everi
year
thereaft
addit
pft
perform
patient
pulmonari
symptom
could
explain
activ
infect
total
lung
capac
fvc
fvc
co
diffus
capac
correct
hemoglobin
level
determin
result
report
percentag
predict
normal
valu
bo
consid
differenti
diagnosi
signific
persist
declin
compar
pretransplant
baselin
level
occur
howev
treat
physician
suspect
bo
base
symptom
clinic
find
videoassist
thoracoscop
surgeri
vat
also
consid
patient
less
pronounc
chang
surgeri
routin
workup
includ
hrct
bal
hrct
scan
result
analyz
experienc
radiologist
intraand
extrapulmonari
patholog
includ
pulmonari
infiltr
bronchial
wall
thicken
increas
bronchial
diamet
compar
accompani
bronchial
arteri
bronchiectasi
air
trap
patient
underw
bal
exclud
infect
caus
pulmonari
symptom
lung
function
declin
cytopatholog
analysi
lavag
fluid
includ
total
differenti
cell
count
direct
stain
bacteri
fungal
organ
recent
year
ad
addit
analys
includ
immunofluoresc
stain
pneumocysti
cytomegaloviru
respiratori
syncyti
viru
rsv
proven
infect
exclus
criterion
lung
biopsi
patient
show
persist
declin
pft
lung
biopsi
perform
vat
except
first
patient
open
lung
biopsi
biopsi
usual
taken
lobe
well
area
involv
hrct
scan
lung
wedg
resect
inflat
fix
buffer
formalin
paraffin
embed
specimen
cut
section
routin
stain
hematoxylin
eosin
elastica
van
gieson
alcian
blueperiod
acid
schiff
grocott
methenamin
silver
stain
specimen
review
blind
manner
lung
pathologist
involv
initi
diagnosi
lb
ss
histolog
find
suggest
viral
infect
nuclear
enlarg
clear
smudg
multinucl
immunohistochem
analys
cytomegaloviru
herp
simplex
viru
adenoviru
also
perform
two
distinct
histolog
pattern
bronchiol
identifi
constrict
bronchiol
obliteran
cbo
figur
lymphocyt
bronchiol
lb
figur
cbo
character
concentr
eccentr
deposit
fibrou
tissu
within
submucosa
bronchiol
without
minim
chronic
inflamm
contrast
lb
character
promin
lymphocyt
infiltr
bronchiolar
wall
variabl
epitheli
inflamm
damag
third
group
compris
patient
specif
patholog
diagnos
diagnosi
lung
patholog
regular
followup
pft
routin
perform
obtain
biopsi
result
patient
biopsyproven
bronchiol
receiv
new
increas
immunosuppress
therapi
includ
calcineurin
inhibitor
mainli
tacrolimu
except
patient
sever
renal
insuffici
sirolimu
use
intoler
cyclosporin
use
mycophenol
acid
prednison
initi
prednison
delay
day
surgeri
allow
wound
heal
initi
dose
usual
mgkg
day
follow
mgkg
anoth
week
subsequ
taper
mg
everi
week
mg
daili
afterward
steroid
taper
slowli
mg
mg
mg
mg
everi
week
depend
stabil
improv
pft
mycophenol
acid
ad
base
vitro
data
show
potent
antiprolif
effect
lung
fibroblast
soon
system
steroid
dose
mg
treatment
inhal
steroid
twice
daili
start
azithromycin
mg
time
weekli
ad
antiinflammatori
action
becam
evid
type
therapi
outcom
base
improv
pft
result
surviv
analyz
data
diagnosi
condit
regimen
graft
sourc
gvhd
prophylaxi
smoke
histori
allergi
gvhd
collect
retrospect
chart
review
followup
current
juli
approv
local
institut
review
board
obtain
studi
patient
surviv
determin
use
kaplanmei
method
mannwhitney
u
test
use
compar
variabl
among
cbo
lb
group
multipl
comparison
kruskalw
test
use
comparison
cbo
lb
cbo
infect
cboi
analysi
varianc
use
multipl
comparison
p
valu
consid
statist
signific
analys
p
valu
consid
statist
signific
analys
perform
use
ibm
spss
version
ibm
armonk
ny
last
nearli
year
surgic
lung
resect
regularli
perform
center
hematolog
patient
neutropenia
posttransplant
earlier
year
main
reason
lung
resect
fungal
infect
sinc
major
surgic
lung
resect
patient
allogen
hsct
ie
patient
diagnost
reason
earli
late
transplant
diagnost
question
depend
time
posttransplant
clinic
characterist
twentyseven
biopsi
perform
diagnos
exclud
bo
time
period
compris
patient
bo
suspect
base
criteria
describ
three
patient
proceed
vat
either
patient
deferr
n
lung
reserv
consid
poor
n
biopsi
patient
perform
suspicion
bo
repres
patient
would
qualifi
procedur
time
period
exact
reason
undergo
lung
biopsi
could
ascertain
case
includ
medic
reason
comorbid
lung
function
consid
poor
allow
lung
surgeri
accept
risk
patient
refus
henc
patient
lung
biopsi
perform
initi
suspicion
bo
identifi
ten
histolog
proven
cbo
cboi
one
piv
rsv
lb
lb
concomit
infect
piv
rsv
one
one
patient
cbo
lb
lesion
identifi
assum
constrict
lesion
would
primarili
determin
cours
diseas
patient
includ
cbo
group
analysi
remain
patient
histolog
diagnos
made
includ
mucu
plug
n
organ
pneumonia
n
venoocclus
diseas
lung
fibrosi
n
patient
diseas
characterist
shown
tabl
tabl
show
transplant
characterist
base
patholog
find
median
age
transplant
year
rang
year
patient
match
relat
hlamatch
unrel
donor
peripher
blood
stem
cell
frequent
use
stem
cell
sourc
twentyf
patient
follow
intens
myeloabl
condit
regimen
includ
busulfan
patient
major
gvhd
prophylaxi
includ
cyclosporin
methotrex
n
median
time
interv
hsct
cbo
diagnosi
day
rang
day
interv
hsct
lb
diagnosi
mean
day
rang
day
p
diagnosi
main
symptom
cough
mainli
nonproduct
n
cbo
group
n
lb
group
dyspnea
n
cbo
group
n
lb
group
median
baselin
valu
allogen
hsct
differ
patient
later
diagnos
cbo
rang
cboi
rang
lb
without
infect
rang
tabl
figur
furthermor
time
biopsi
signific
differ
median
valu
group
cbo
rang
cboi
rang
lb
rang
median
declin
baselin
time
biopsi
perform
cbo
cboi
lb
declin
pft
statist
signific
group
cbo
p
cboi
p
lb
p
three
patient
normal
hrct
cbo
lb
group
increas
bronchial
wall
thicken
frequent
radiolog
find
group
cbo
lb
group
tabl
sixteen
patient
inand
expiratori
hrct
scan
cboi
patient
cboi
patient
lb
patient
lbi
patient
mosaic
pattern
expir
infiltr
seen
patient
none
radiolog
find
pathognomon
either
cbo
lb
histolog
diagnosi
known
sensit
ct
find
could
determin
among
patient
confirm
cbo
increas
bronchial
wall
thick
found
increas
bronchial
diamet
compar
correspond
arteri
mosaic
pattern
expir
correspond
valu
patient
lb
respect
tabl
summar
nihcriteria
accord
histolog
group
patient
patient
underw
bal
procedur
result
shown
tabl
differenti
cell
count
avail
patient
concomit
viral
infect
identifi
patient
piv
rsv
patient
lb
compar
patient
cbo
significantli
higher
proport
lymphocyt
p
signific
differ
differenti
cell
count
group
vat
procedur
perform
median
day
bal
inhospit
postop
mortal
entir
group
twentysix
patient
experi
postop
complic
six
patient
surgeryrel
minor
complic
prolong
pain
n
prolong
air
leak
n
one
patient
experienc
pain
hypesthesia
open
lung
surgeri
anoth
patient
develop
late
empyema
day
vat
possibl
relat
procedur
one
intub
patient
indic
vat
persist
pneumothorax
suspect
bo
final
diagnosi
venoocclus
diseas
lung
patient
remain
intub
underw
success
urgent
lung
transplant
day
vat
patient
cbo
group
lb
group
treat
calcineurin
inhibitor
cyclosporin
tacrolimu
one
patient
lb
treat
sirolimu
rather
calcineurin
inhibitor
cbo
lb
group
receiv
mycophenol
mofetil
well
macrolid
cbo
group
lb
group
patient
cbo
treat
system
steroid
patient
lb
one
treat
mgday
median
durat
steroid
treatment
dosag
mgday
week
rang
week
cbo
week
rang
week
lb
group
slight
signific
trend
less
intens
steroid
treatment
lb
group
p
patient
infect
either
rsv
piv
treat
intraven
immunoglobulin
rsv
ribavirin
median
followup
time
obtain
lung
biopsi
day
rang
cbo
group
day
rang
lb
group
p
median
followup
time
biopsi
surviv
patient
day
rang
cbo
day
rang
lb
group
p
one
patient
cbo
group
underw
lung
transplant
henc
followup
censor
time
lung
transplant
patient
aliv
month
lung
transplant
predict
valu
followup
biopsi
signific
increment
median
cbo
cboi
group
contrast
lb
group
exhibit
statist
signific
increas
median
month
diagnosi
p
maintain
improv
month
p
median
group
differ
statist
upon
month
diagnosi
neither
cbo
cboi
group
regain
baselin
valu
figur
lb
group
month
diagnosi
also
significantli
lower
compar
baselin
differ
longer
detect
month
slight
trend
lower
compar
baselin
last
followup
statist
signific
differ
median
valu
group
cbo
rang
versu
lb
rang
p
surviv
analysi
patient
infect
present
time
diagnosi
includ
correspond
group
assum
resolut
initi
infect
surviv
would
mainli
depend
histolog
characterist
figur
show
kaplanmei
surviv
curv
tabl
histolog
versu
nih
criteria
patient
cbo
lb
patient
surviv
year
respect
patient
cbo
patient
lb
p
observ
period
patient
cbo
die
wherea
patient
lb
die
patient
cbo
caus
death
relaps
andor
progress
underli
diseas
n
sepsi
n
respiratori
failur
n
secondari
malign
n
sepsi
caus
death
patient
lb
three
eight
patient
histolog
diagnos
cbo
lb
die
followup
period
respiratori
insuffici
secondari
malign
myocardi
infarct
retrospect
singlecent
studi
includ
patient
allogen
hsct
underw
lung
biopsi
suspect
bo
although
practic
decisionmak
entir
consist
decad
less
rigor
earlier
year
rather
strict
algorithm
follow
last
year
biopsi
perform
even
though
studi
design
valid
current
nih
consensu
criteria
bo
sever
import
observ
made
first
patient
similar
clinic
present
found
distinct
histolog
entiti
classic
cbo
character
deposit
fibrou
tissu
lb
character
lymphocyt
infiltr
bronchiolar
wall
without
signific
fibrosi
neither
pft
result
hrct
find
time
vat
predict
histolog
find
although
bal
show
significantli
higher
proport
lymphocyt
lb
group
found
use
clinic
practic
wide
overlap
distribut
rang
second
cohort
patient
cbo
lb
met
current
nih
consensu
bo
definit
hand
patient
patient
cohort
histolog
confirm
cbo
meet
consensu
concomit
airway
infect
furthermor
although
small
patient
number
sign
air
trap
hrct
scan
seen
histolog
proven
cbo
henc
current
definit
includ
patient
differ
histolog
entiti
may
miss
patient
cbo
may
impact
interpret
therapeut
intervent
trial
result
histolog
confirm
bo
done
result
confirm
current
nih
consensu
bo
definit
may
need
modifi
increas
sensit
addit
suspicion
evolv
bo
remain
high
even
presenc
infect
final
result
confirm
biopsi
remain
gold
standard
diagnosi
bo
outlin
nih
consensu
document
statement
support
fact
found
distinct
patholog
diagnos
patient
strong
suspicion
bo
least
nt
requir
intensifi
immunosuppress
therapi
third
current
avail
surgic
techniqu
appli
skill
surgeon
vat
perform
low
complic
rate
periop
risk
result
compar
favor
previou
studi
report
lung
biopsi
associ
signific
morbid
mortal
rang
skill
surgeon
progress
made
minim
invas
surgic
techniqu
periop
patient
care
might
contribut
improv
studi
sever
limit
import
retrospect
natur
small
number
patient
howev
rariti
bo
fact
center
seek
histolog
diagnosi
studi
best
knowledg
largest
kind
report
far
retrospect
design
lack
repeat
biopsi
followup
allow
gener
hypothes
henc
remain
open
question
cbo
lb
repres
differ
stage
diseas
process
differ
entiti
seem
reason
inflammatori
process
like
lb
preced
fibrosi
observ
cbo
also
describ
case
report
pathophysiolog
cbo
remain
elucid
prospect
studi
histolog
find
translat
yet
differ
treatment
strategi
treatment
mainli
guid
cours
pft
similar
immunosuppress
treatment
recoveri
lung
function
measur
surviv
strikingli
differ
group
henc
hypothesi
true
result
suggest
intens
immunosuppress
may
abl
revers
pathophysiolog
process
bronchiol
detect
earli
stage
inflammatori
chang
predomin
prevent
develop
fibrosi
thu
alter
otherwis
poor
prognosi
evolv
bo
constrict
chang
alreadi
establish
intens
immunosuppress
lead
improv
airway
narrow
may
even
contribut
deterior
lung
function
increas
suscept
infect
increas
risk
relaps
andor
develop
secondari
malign
patient
new
antiprolif
approach
need
investig
conclus
lung
biopsi
patient
suspect
bo
better
character
bo
pattern
follow
allogen
hsct
contrast
cbo
lb
may
repres
inflammatori
statu
preced
cbo
associ
good
longterm
prognosi
understand
pathophysiolog
bo
necessari
develop
appropri
strategi
earli
diagnosi
treatment
sever
posttransplant
complic
hospit
basel
excel
contribut
patient
care
sampl
analysi
conflict
interest
statement
author
report
potenti
conflict
interest
authorship
statement
ah
tl
jph
mt
design
studi
draft
manuscript
ah
tl
sg
collect
data
ah
tl
ms
statist
analysi
fg
dl
perform
lung
biopsi
lb
ss
evalu
biopsi
pg
mt
analyz
pft
perform
bal
author
contribut
data
analysi
data
interpret
write
manuscript
ah
tl
contribut
equal
manuscript
mt
jph
contribut
equal
manuscript
financi
disclosur
author
noth
disclos
